141 related articles for article (PubMed ID: 33228419)
21. Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
Yoshida-Court K; Karpinets TV; Mitra A; Solley TN; Dorta-Estremera S; Sims TT; Delgado Medrano AY; El Alam MB; Ahmed-Kaddar M; Lynn EJ; Sastry KJ; Zhang J; Futreal A; Nick A; Lu K; Colbert LE; Klopp AH
PLoS One; 2023; 18(1):e0279590. PubMed ID: 36607962
[TBL] [Abstract][Full Text] [Related]
22. High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma.
Yamamoto A; Kurata M; Yamamoto K; Nogawa D; Inoue M; Ishibashi S; Ikeda M; Miyasaka N; Kitagawa M
Pathol Res Pract; 2020 Nov; 216(11):153175. PubMed ID: 32841774
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
24. Clinicopathological parameters and survival of invasive epithelial ovarian cancer by histotype and disease stage.
Lan A; Yang G
Future Oncol; 2019 Jun; 15(17):2029-2039. PubMed ID: 31140868
[No Abstract] [Full Text] [Related]
25. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract][Full Text] [Related]
27. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
[TBL] [Abstract][Full Text] [Related]
28. Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?
Yildirim N; Akman L; Acar K; Demir S; Ozkan S; Alan N; Zekioglu O; Terek MC; Ozdemir N; Ozsaran A
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():55-61. PubMed ID: 28601728
[TBL] [Abstract][Full Text] [Related]
29. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
30. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
van Dongen JJ; Langerak AW; Brüggemann M; Evans PA; Hummel M; Lavender FL; Delabesse E; Davi F; Schuuring E; García-Sanz R; van Krieken JH; Droese J; González D; Bastard C; White HE; Spaargaren M; González M; Parreira A; Smith JL; Morgan GJ; Kneba M; Macintyre EA
Leukemia; 2003 Dec; 17(12):2257-317. PubMed ID: 14671650
[TBL] [Abstract][Full Text] [Related]
31. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome.
Baleydier F; Decouvelaere AV; Bergeron J; Gaulard P; Canioni D; Bertrand Y; Lepretre S; Petit B; Dombret H; Beldjord K; Molina T; Asnafi V; Macintyre E
Clin Cancer Res; 2008 Feb; 14(3):692-700. PubMed ID: 18245528
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of pelvic and para-aortic lymphadenectomy on clinically-apparent stage I primary mucinous epithelial ovarian carcinoma: a multi-institutional study with propensity score-weighted analysis.
Yoshihara M; Kajiyama H; Tamauchi S; Iyoshi S; Yokoi A; Suzuki S; Kawai M; Nagasaka T; Takahashi K; Matsui S; Kikkawa F
Jpn J Clin Oncol; 2020 Feb; 50(2):145-151. PubMed ID: 31688935
[TBL] [Abstract][Full Text] [Related]
33. Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.
Hagemann AR; Cadungog M; Hagemann IS; Hammond R; Adams SF; Chu CS; Rubin SC; Zhang L; Addya K; Birrer MJ; Gimotty PA; Coukos G
Cancer Biol Ther; 2011 Aug; 12(4):357-66. PubMed ID: 21785264
[TBL] [Abstract][Full Text] [Related]
34. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
Bachmayr-Heyda A; Aust S; Heinze G; Polterauer S; Grimm C; Braicu EI; Sehouli J; Lambrechts S; Vergote I; Mahner S; Pils D; Schuster E; Thalhammer T; Horvat R; Denkert C; Zeillinger R; Castillo-Tong DC
BMC Cancer; 2013 Sep; 13():422. PubMed ID: 24044611
[TBL] [Abstract][Full Text] [Related]
36. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
[TBL] [Abstract][Full Text] [Related]
37. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
38. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas.
Gurkan D; Ceren Akin A; Sahin H; Aytac Tohma Y; Sahin EA; Gunakan E; Iflazoglu N; Nihan Haberal A; Ayhan A
J Obstet Gynaecol; 2020 May; 40(4):551-557. PubMed ID: 31482736
[TBL] [Abstract][Full Text] [Related]
39. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
40. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2.
He WP; Guo YY; Yang GP; Lai HL; Sun TT; Zhang ZW; Ouyang LL; Zheng Y; Tian LM; Li XH; You ZS; Xie D; Yang GF
Int J Med Sci; 2020; 17(15):2387-2395. PubMed ID: 32922205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
